FindTrial
Sign In

Randomised Controlled Trial of CID versus CD for Induction of Remission in Low Grade Non-Hodgkin's Lymphoma and Randomised Controlled Assessment of Interferon as Maintenance Treatment after Remission Induction

Randomised Controlled Trial of CID versus CD for Induction of Remission in Low Grade Non-Hodgkin's Lymphoma and Randomised Controlled Assessment of Interferon as Maintenance Treatment after Remission Induction

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN53211392
Enrollment
Unknown
Registered
2002-08-19
Start date
1995-01-01
Completion date
Unknown
Last updated
2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lymphoma (non-Hodgkin's) Cancer

Interventions

INDUCTION / CONSOLIDATION: Patients are randomised to one of two treatment arms: 1. Arm A: Chemotherapy with Chlorambucil, idarubicin and dexamethasone (CID), cycle to be repeated every 21 days. Pati

Sponsors

Scotland & Newcastle Lymphoma Group (UK)
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Kiel classification of low grade non-Hodgkin's lymphoma 2. Stages II to IV 3. Age 15 to 70 years 4. Measurable disease 5. No prior chemotherapy 6. No central nervous system (CNS) involvement 7. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 8. Adequate bone marrow, renal and hepatic function 9. No medical contraindications to protocol treatments

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Primary

MeasureTime frame
Not provided at time of registration—

Secondary

MeasureTime frame
Not provided at time of registration—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026